GENE ONLINE|News &
Opinion
Blog

2022-08-01| Special

BIO 2022: Options for Raising Capital in a Down Market

by Richard Chau
Share To
From left to right: Celia Economides (Moderator), Igor DaCruz, Cecilia Gonzalo, Marshall Urist, MD, PhD

The current stock market environment for small biotechs is tough even by historical standards. Many biotechs are now trading below cash value and IPOs have slowed significantly. In the current environment, companies are having to consider alternative methods for raising capital to advance clinical trials and R&D pipelines.

In a panel discussion at the 2022 BIO International Convention (BIO2022), experts in biotech investment and capital management covered some of these specialized financing mechanisms, such as private investments in public entities (PIPEs), royalty deals, and other structured deals that use pipelines as collateral. Moderated by Celia Economides, Executive Vice President and Chief Financial Officer at Gritstone Bio, the session included:
Igor DaCruz, Managing Director at Runway Growth Capital
Cecilia Gonzalo, Partner at Oberland Capital Management
Marshall Urist, MD, PhD, Executive Vice President and Head of Research & Investment of Royalty Pharma Management, LLC

It's free! Log in now to read

LATEST
AstraZeneca Welcomes Neurofibromatosis And Asthma Treatment Approvals in Japan
2022-09-28
Biogen Concludes $900 Million Settlement Before Posting Positive Data From Alzheimer’s Trial
2022-09-28
Arsenal Biosciences Announced Another $70 million Collaboration, This Time With Genentech
2022-09-27
Sciwind Biosciences And SynerK Join Forces To Develop siRNA Therapeutics
2022-09-27
Acticor Enrolls First Patient in Phase 2/3 Stroke Treatment Study
2022-09-27
Daiichi Sankyo Wins Approval For Cancer Treatment in Japan
2022-09-26
Seagen Strikes Potential $650 million Deal with LAVA Therapeutics for Cancer Treatment
2022-09-26
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!